New Vaccine Successfully Tested in Latent TB Infection
MVA85A produced immunogenic response without immunopathology in phase 1 trial
FRIDAY, April 10 (HealthDay News) -- A new vaccine for tuberculosis produced immunogenic response without immunopathology in patients with latent tuberculosis infection, according to the results of a study published in the April 15 issue of the American Journal of Respiratory and Critical Care Medicine.
Clare R. Sander, of the Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford in the United Kingdom, and colleagues recruited 12 patients with latent tuberculosis infection, which can cause full-blown TB. The patients were vaccinated with the new vaccine, recombinant modified vaccinia Ankara expressing antigen 85A (MVA85A), and then followed-up for 12 months.
The researchers found no significant adverse changes in inflammatory markers or on computed tomography scans following vaccination. The vaccine induced a strong immunogenic response that lasted throughout the 12-month study period. No immunopathology was observed and side effects were mild vaccination site effects, headache and fatigue.
"MVA85A is safe and highly immunogenic in individuals with latent tuberculosis infection. These results will facilitate further trials in TB-endemic areas," the authors conclude.